Chronic neuropathic pain is a condition caused by damage or disease affecting the somatosensory nervous system. According to the International Association for the Study of Pain (IASP), neuropathic pain affects approximately 7-10% of the global population. According to the chronic neuropathic pain pipeline analysis by Expert Market Research, the therapeutic landscape includes tricyclic antidepressants, SNRIs, and gabapentinoids, with over 100 novel drugs in development targeting unmet patient needs. Growing focus on non-opioid therapies, precision medicine, and innovative delivery mechanisms is expected to drive substantial growth in the coming years, reflecting rising prevalence and increasing healthcare awareness.
Major companies involved in the chronic neuropathic pain pipeline analysis include Beijing Tide Pharmaceutical Co., Ltd., Sangamo Therapeutics, and others.
Leading drugs currently in the pipeline include TRD205, ST-503, and others.
The pipeline shows significant growth driven by novel sodium channel modulators, selective ion-channel therapies, and biologics targeting neuropathic signaling, with increasing clinical trials expanding treatment options and market potential globally.
The Chronic Neuropathic Pain Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic neuropathic pain therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic neuropathic pain. The chronic neuropathic pain report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic neuropathic pain pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic neuropathic pain treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic neuropathic pain.
Read more about this report - Request a Free Sample
Chronic neuropathic pain is a persistent condition caused by damage or dysfunction in the peripheral or central nervous system. It occurs when nerve signaling becomes abnormal, often triggered by inflammation, injury, or metabolic disorders, resulting in burning, tingling, or shooting pain that can severely affect quality of life.
Chronic neuropathic pain treatments include anticonvulsants, antidepressants, topical agents, and emerging neuromodulation therapies aimed at reducing abnormal nerve signaling and managing symptoms effectively. In July 2025, Monash University researchers reported a promising chronic neuropathic pain drug pipeline candidate targeting the adenosine A1 receptor. These selective positive allosteric modulators enhance receptor activity, offering pain relief with minimal cardiac side effects.
According to the International Association for the Study of Pain, neuropathic pain affects approximately 7-10% of the general population. In Europe, the prevalence is estimated at 7%–8%, as reported by Anas Hamdan et al., 2024. Globally, chronic pain impacts 2%–40% of individuals, with 27%–58% of people aged 65 years and older experiencing this condition, according to Ambrish Singh et al., 2024. These trends highlight the ongoing need for novel therapeutic developments in the chronic neuropathic pain pipeline.
This section of the report covers the analysis of chronic neuropathic pain drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The chronic neuropathic pain pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 35%, covers a major share of the total chronic neuropathic pain clinical trials. It is followed by phase I and phase IV, each at 23%. Phase III accounts for 15.38%. This strong distribution across clinical phases indicates robust development activity, suggesting a promising future for innovative therapies and potential market growth.
The drug molecule categories covered under the chronic neuropathic pain pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The chronic neuropathic pain report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic neuropathic pain. Selective peripheral sodium channel blockers are gaining attention in the chronic neuropathic pain pipeline. For example, VX-548, a Nav1.8 inhibitor developed by Vertex Pharmaceuticals, is under evaluation for reducing post-surgical and chronic nerve pain. Additionally, other Nav1.7-targeting compounds are being investigated to modulate dorsal root ganglion neuron hyperactivity, offering potential non-addictive, non-sedating alternatives for patients unresponsive to current therapies.
The EMR report for the chronic neuropathic pain pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic neuropathic pain therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic neuropathic pain clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic neuropathic pain. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic neuropathic pain drug candidates.
TRD205 is a first-in-class AT2R antagonist developed by Beijing Tide Pharmaceutical Co., Ltd. This Phase II, multicenter, randomized, double-blind, placebo-controlled, dose-finding study is evaluating the efficacy, safety, and pharmacokinetics of TRD205 tablets in treating chronic postoperative neuralgia. The study is examining multiple dose regimens to determine optimal therapeutic outcomes. TRD205 is designed as a non-opioid therapy, selectively blocking AT2R activation, offering effective pain relief while minimizing risks of addiction and respiratory depression.
ST-503 is a gene therapy drug sponsored by Sangamo Therapeutics, designed to target chronic neuropathic pain associated with idiopathic small fiber neuropathy (iSFN). This Phase 1 study is examining the safety and tolerability of a single intrathecal dose of ST-503. The drug delivers an engineered zinc finger repressor via an AAV vector to selectively suppress the SCN9A gene, reducing Nav1.7 sodium channels in sensory neurons and potentially alleviating refractory pain. The trial is expected to commence in October 2025 with estimated completion in July 2028, enrolling 27 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Chronic Neuropathic Pain Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic neuropathic pain. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic neuropathic pain collaborations, regulatory environments, and potential growth opportunities.
Diabetic Neuropathic Pain Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share